Mini-Review Article

胃癌化疗耐药的分子机制,自噬的作用

卷 21, 期 7, 2020

页: [713 - 721] 页: 9

弟呕挨: 10.2174/1389450120666191127113854

价格: $65

摘要

胃癌(GC)在生物学和遗传上具有异质性,在分子水平上具有复杂的致癌作用。尽管在GC治疗中采用了多种方法,但其5年生存率很低。抗癌药物应用的主要局限性是内在或获得性耐药,尤其是对化学治疗剂的耐药。众所周知,化学疗法的有效性仍然值得商and,并且根据GC的分子类型而有所不同。化学疗法在GC的管理中具有确定的作用。围手术期化疗或局部术后化疗。大多数晚期GC患者对标准疗法的治疗反应较差且预后不良。抗药性实质上限制了针对靶向抗癌疗法的临床反应的深度和持续时间。通过使用互补的实验方法,研究人员发现癌细胞可以通过特定遗传,表观遗传或微环境改变驱动的适应或选择来实现抗药性。最终,这些多样的改变通常会导致MAPK,AKT / mTOR和Wnt /β-catenin信号通路的激活,这些通路在被共同采用时可使癌细胞在药物治疗中幸存下来。我们总结了在GC管理中对顺铂,5-氟尿嘧啶和多药耐药性产生耐药性的机制。在抗药性发展中,改变分子靶标和信号转导级联的复杂性导致在GC治疗中没有明显的益处,并且其功效仍然很低。导致GC治疗多峰方法失败的普遍过程是自噬。它在肿瘤发生中的双重作用是最无法探索的问题。我们已经讨论了自噬调节内源性因子和药物作用的可能机制。在培养的GC细胞中获得的实验数据需要进一步验证。为了克服抗癌性并防止自噬是治疗无效的主要原因,建议先考虑自噬分子标记物的直接影响,然后再进行标准化疗。数十项研究集中在寻找这种复杂疗法的益处的原理。 GC的基于分子管理的观点与预测保护性自噬启动和寻找有效抗癌治疗新靶标的分子标志物的开发有关。

关键词: 分子诊断和治疗,化学疗法,肿瘤标志物,自噬,抗癌治疗,胃癌(GC)。

图形摘要

[1]
Berretta S, Berretta M, Fiorica F, et al. Multimodal approach of advanced gastric cancer: based therapeutic algorithm. Eur Rev Med Pharmacol Sci 2016; 20(19): 4018-31.
[PMID: 27775797]
[2]
Pietrantonio F, De Braud F, Da Prat V, et al. A review on biomarkers for prediction of treatment outcome in gastric cancer. Anticancer Res 2013; 33(4): 1257-66.
[PMID: 23564763]
[3]
Tomczak K, Czerwińska P, Wiznerowicz M. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemp Oncol (Pozn) 2015; 19(1A): A68-77.
[http://dx.doi.org/10.5114/wo.2014.47136] [PMID: 25691825]
[4]
Stewart C, Chao J, Chen YJ, et al. Multimodality management of locally advanced gastric cancer-the timing and extent of surgery. Transl Gastroenterol Hepatol 2019; 4: 42.
[http://dx.doi.org/10.21037/tgh.2019.05.02] [PMID: 31231709]
[5]
Zhang H, Fan Q, Wei X. Chemotherapy sensitivity of gastric cancer. Clin Surg 2017; 2: 1400.
[PMID: 28255193]
[6]
Matsuoka T, Yashiro M. Biomarkers of gastric cancer: Current topics and future perspective. World J Gastroenterol 2018; 24(26): 2818-32.
[http://dx.doi.org/10.3748/wjg.v24.i26.2818] [PMID: 30018477]
[7]
Wang S, Yuan L. Predictive biomarkers for targeted and cytotoxic agents in gastric cancer for personalized medicine. Biosci Trends 2016; 10(3): 171-80.
[http://dx.doi.org/10.5582/bst.2016.01078] [PMID: 27251446]
[8]
Jiang GM, Tan Y, Wang H, et al. The relationship between autophagy and the immune system and its applications for tumor immunotherapy. Mol Cancer 2019; 18(1): 17.
[http://dx.doi.org/10.1186/s12943-019-0944-z] [PMID: 30678689]
[9]
Spirina LV, Kondakova IV, Tarasenko NV, et al. Targeting of the akt/m-tor pathway: biomarkers of resistance to cancer therapy--
akt/m-tor pathway and resistance to cancer therapy. Zhongguo Fei Ai Za Zhi 2018; 21(1): 63-6.
[http://dx.doi.org/10.3779/j.issn.1009-3419.2018.01.09] [PMID: 29357975]
[10]
Marin JJ, Monte MJ, Blazquez AG, Macias RI, Serrano MA, Briz O. The role of reduced intracellular concentrations of active drugs in the lack of response to anticancer chemotherapy. Acta Pharmacol Sin 2014; 35(1): 1-10.
[http://dx.doi.org/10.1038/aps.2013.131] [PMID: 24317012]
[11]
Jögi A, Vaapil M, Johansson M, Påhlman S. Cancer cell differentiation heterogeneity and aggressive behavior in solid tumors. Ups J Med Sci 2012; 117(2): 217-24.
[http://dx.doi.org/10.3109/03009734.2012.659294] [PMID: 22376239]
[12]
Spirina LV, Usynin YA, Yurmazov ZA, Slonimskaya EM, Kolegova ES, Kondakova IV. Transcription factors NF-kB, HIF-1, HIF-2, growth factor VEGF, VEGFR2 and carboanhydrase IX mRNA and protein level in the development of kidney cancer metastasis Mol Biol (Mosk) 2017; 51(2): 372-7.
[http://dx.doi.org/10.7868/S0026898417020197] [PMID: 28537244]
[13]
Xing M. Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer. Thyroid 2010; 20(7): 697-706.
[http://dx.doi.org/10.1089/thy.2010.1646] [PMID: 20578891]
[14]
Haagenson KK, Wu GS. The role of MAP kinases and MAP kinase phosphatase-1 in resistance to breast cancer treatment. Cancer Metastasis Rev 2010; 29(1): 143-9.
[http://dx.doi.org/10.1007/s10555-010-9208-5] [PMID: 20111893]
[15]
Hientz K, Mohr A, Bhakta-Guha D, Efferth T. The role of p53 in cancer drug resistance and targeted chemotherapy. Oncotarget 2017; 8(5): 8921-46.
[http://dx.doi.org/10.18632/oncotarget.13475] [PMID: 27888811]
[16]
García-Aranda M, Pérez-Ruiz E, Redondo M. Bcl-2 Inhibition to Overcome Resistance to Chemo- and Immunotherapy. Int J Mol Sci 2018; 19(12)E3950
[http://dx.doi.org/10.3390/ijms19123950] [PMID: 30544835]
[17]
Du B, Shim JS. Targeting epithelial-mesenchymal transition (emt) to overcome drug resistance in cancer. Molecules 2016; 21(7)E965
[http://dx.doi.org/10.3390/molecules21070965] [PMID: 27455225]
[18]
Cui J, Jiang W, Wang S, Wang L, Xie K. Role of Wnt/β-catenin signaling in drug resistance of pancreatic cancer. Curr Pharm Des 2012; 18(17): 2464-71.
[http://dx.doi.org/10.2174/13816128112092464] [PMID: 22372504]
[19]
Dehghanzadeh R, Jadidi-Niaragh F, Gharibi T, Yousefi M. MicroRNA-induced drug resistance in gastric cancer. Biomed Pharmacother 2015; 74: 191-9.
[http://dx.doi.org/10.1016/j.biopha.2015.08.009] [PMID: 26349984]
[20]
Wood KC. Mapping the pathways of resistance to targeted therapies. Cancer Res 2015; 75(20): 4247-51.
[http://dx.doi.org/10.1158/0008-5472.CAN-15-1248] [PMID: 26392071]
[21]
Yang W, Ma J, Zhou W, et al. Molecular mechanisms and theranostic potential of miRNAs in drug resistance of gastric cancer. Expert Opin Ther Targets 2017; 21(11): 1063-75.
[http://dx.doi.org/10.1080/14728222.2017.1389900] [PMID: 28994330]
[22]
Wang P, Li Z, Liu H, Zhou D, Fu A, Zhang E. MicroRNA-126 increases chemosensitivity in drug-resistant gastric cancer cells by targeting EZH2. Biochem Biophys Res Commun 2016; 479(1): 91-6.
[http://dx.doi.org/10.1016/j.bbrc.2016.09.040] [PMID: 27622325]
[23]
Huang H, Tang J, Zhang L, Bu Y, Zhang X. miR-874 regulates multiple-drug resistance in gastric cancer by targeting ATG16L1. Int J Oncol 2018; 53(6): 2769-79.
[http://dx.doi.org/10.3892/ijo.2018.4593] [PMID: 30320370]
[24]
Zhang X, Bo P, Liu L, Zhang X, Li J. Overexpression of long non-coding RNA GHET1 promotes the development of multidrug resistance in gastric cancer cells. Biomed Pharmacother 2017; 92: 580-5.
[http://dx.doi.org/10.1016/j.biopha.2017.04.111] [PMID: 28578256]
[25]
Wang SF, Chen MS, Chou YC, et al. Mitochondrial dysfunction enhances cisplatin resistance in human gastric cancer cells via the ROS-activated GCN2-eIF2α-ATF4-xCT pathway. Oncotarget 2016; 7(45): 74132-51.
[http://dx.doi.org/10.18632/oncotarget.12356] [PMID: 27708226]
[26]
Mo D, Fang H, Niu K, et al. Human helicase recql4 drives cisplatin resistance in gastric cancer by activating an akt-yb1-mdr1 signaling pathway. Cancer Res 2016; 76(10): 3057-66.
[http://dx.doi.org/10.1158/0008-5472.CAN-15-2361] [PMID: 27013200]
[27]
Wang L, Chunyan Q, Zhou Y, et al. BCAR4 increase cisplatin resistance and predicted poor survival in gastric cancer patients. Eur Rev Med Pharmacol Sci 2017; 21(18): 4064-70.
[PMID: 29028095]
[28]
Ye XL, Zhao YR, Weng GB, et al. IL-33-induced JNK pathway activation confers gastric cancer chemotherapy resistance. Oncol Rep 2015; 33(6): 2746-52.
[http://dx.doi.org/10.3892/or.2015.3898] [PMID: 25846650]
[29]
Lu C, Shan Z, Li C, Yang L. MiR-129 regulates cisplatin-resistance in human gastric cancer cells by targeting P-gp. Biomed Pharmacother 2017; 86: 450-6.
[http://dx.doi.org/10.1016/j.biopha.2016.11.139] [PMID: 28012924]
[30]
Zheng P, Chen L, Yuan X, et al. Exosomal transfer of tumor-associated macrophage-derived miR-21 confers cisplatin resistance in gastric cancer cells. J Exp Clin Cancer Res 2017; 36(1): 53.
[http://dx.doi.org/10.1186/s13046-017-0528-y] [PMID: 28407783]
[31]
Zhao J, Nie Y, Wang H, Lin Y. MiR-181a suppresses autophagy and sensitizes gastric cancer cells to cisplatin. Gene 2016; 576(2 Pt 2): 828-33.
[http://dx.doi.org/10.1016/j.gene.2015.11.013] [PMID: 26589846]
[32]
Hu XF, Yao J, Gao SG, et al. Nrf2 overexpression predicts prognosis and 5-FU resistance in gastric cancer. Asian Pac J Cancer Prev 2013; 14(9): 5231-5.
[http://dx.doi.org/10.7314/APJCP.2013.14.9.5231] [PMID: 24175806]
[33]
Wang J, Hu W, Wang K, et al. Repertaxin, an inhibitor of the chemokine receptors CXCR1 and CXCR2, inhibits malignant behavior of human gastric cancer MKN45 cells in vitro and in vivo and enhances efficacy of 5-fluorouracil. Int J Oncol 2016; 48(4): 1341-52.
[http://dx.doi.org/10.3892/ijo.2016.3371] [PMID: 26847910]
[34]
Ying LS, Yu JL, Lu XX, Ling ZQ. Enhanced RegIV expression predicts the intrinsic 5-fluorouracil (5-FU) resistance in advanced gastric cancer. Dig Dis Sci 2013; 58(2): 414-22.
[http://dx.doi.org/10.1007/s10620-012-2381-3] [PMID: 23010741]
[35]
Jin J, Lv H, Wu J, et al. Regenerating Family Member 4 (Reg4) Enhances 5-Fluorouracil Resistance of Gastric Cancer Through Activating MAPK/Erk/Bim Signaling Pathway. Med Sci Monit 2017; 23: 3715-21.
[http://dx.doi.org/10.12659/MSM.903134] [PMID: 28759561]
[36]
Chen WY, Huang CY, Cheng WL, et al. Alpha 7-nicotinic acetylcholine receptor mediates the sensitivity of gastric cancer cells to 5-fluorouracil. Tumour Biol 2015; 36(12): 9537-44.
[http://dx.doi.org/10.1007/s13277-015-3668-8] [PMID: 26136123]
[37]
Yu B, Gu D, Zhang X, Liu B, Xie J. The role of GLI2-ABCG2 signaling axis for 5Fu resistance in gastric cancer. J Genet Genomics 2017; 44(8): 375-83.
[http://dx.doi.org/10.1016/j.jgg.2017.04.008] [PMID: 28847472]
[38]
Han Y, Song C, Wang J, Tang H, Peng Z, Lu S. HOXA13 contributes to gastric carcinogenesis through DHRS2 interacting with MDM2 and confers 5-FU resistance by a p53-dependent pathway. Mol Carcinog 2018; 57(6): 722-34.
[http://dx.doi.org/10.1002/mc.22793] [PMID: 29436749]
[39]
Chen D, Jiao XL, Liu ZK, Zhang MS, Niu M. Knockdown of PLA2G2A sensitizes gastric cancer cells to 5-FU in vitro. Eur Rev Med Pharmacol Sci 2013; 17(13): 1703-8.
[PMID: 23852891]
[40]
Kwon OH, Kim JH, Kim SY, Kim YS. TWEAK/Fn14 signaling mediates gastric cancer cell resistance to 5-fluorouracil via NF-κB activation. Int J Oncol 2014; 44(2): 583-90.
[http://dx.doi.org/10.3892/ijo.2013.2211] [PMID: 24337061]
[41]
Kim HM, Kim SA, Park SB, Cho JH, Song SY. Sorafenib inhibits 5-fluorouracil-resistant gastric cancer cell growth. Scand J Gastroenterol 2017; 52(5): 577-84.
[http://dx.doi.org/10.1080/00365521.2017.1278786] [PMID: 28110575]
[42]
He XX, Huang CK, Xie BS. Autophagy inhibition enhanced 5‑FU‑induced cell death in human gastric carcinoma BGC‑823 cells. Mol Med Rep 2018; 17(5): 6768-76.
[http://dx.doi.org/10.3892/mmr.2018.8661] [PMID: 29512733]
[43]
Huang D, Duan H, Huang H, et al. Cisplatin resistance in gastric cancer cells is associated with HER2 upregulation-induced epithelial-mesenchymal transition. Sci Rep 2016; 6: 20502.
[http://dx.doi.org/10.1038/srep20502] [PMID: 26846307]
[44]
Huang R, Gu W, Sun B, Gao L. Identification of COL4A1 as a potential gene conferring trastuzumab resistance in gastric cancer based on bioinformatics analysis. Mol Med Rep 2018; 17(5): 6387-96.
[http://dx.doi.org/10.3892/mmr.2018.8664] [PMID: 29512712]
[45]
Wu M, Guo L, Zuo Q. Correlation between cyclin-dependent kinase inhibitor p27kip1 and trastuzumab-resistance in gastric cancer Zhong Nan Da Xue Xue Bao Yi Xue Ban 2016; 41(5): 471-6.
[http://dx.doi.org/10.11817/j.issn.1672-7347.2016.05.004] [PMID: 27269920]
[46]
Ning L, Guo-Chun Z, Sheng-Li A, et al. Inhibition of autophagy induced by PTEN loss promotes intrinsic breast cancer resistance to trastuzumab therapy. Tumour Biol 2016; 37(4): 5445-54.
[http://dx.doi.org/10.1007/s13277-015-4392-0] [PMID: 26563373]
[47]
Mizushima N. The role of the Atg1/ULK1 complex in autophagy regulation. Curr Opin Cell Biol 2010; 22(2): 132-9.
[http://dx.doi.org/10.1016/j.ceb.2009.12.004] [PMID: 20056399]
[48]
Netea-Maier RT, Klück V, Plantinga TS, Smit JW. Autophagy in thyroid cancer: present knowledge and future perspectives. Front Endocrinol (Lausanne) 2015; 6: 22.
[http://dx.doi.org/10.3389/fendo.2015.00022] [PMID: 25741318]
[49]
Eskelinen EL. Autophagy: Supporting cellular and organismal homeostasis by self-eating. Int J Biochem Cell Biol 2019; 111: 1-10.
[http://dx.doi.org/10.1016/j.biocel.2019.03.010] [PMID: 30940605]
[50]
Pattingre S, Espert L, Biard-Piechaczyk M, Codogno P. Regulation of macroautophagy by mTOR and Beclin 1 complexes. Biochimie 2008; 90(2): 313-23.
[http://dx.doi.org/10.1016/j.biochi.2007.08.014] [PMID: 17928127]
[51]
Yoshii SR, Mizushima N. Monitoring and Measuring Autophagy. Int J Mol Sci 2017; 18(9)E1865
[http://dx.doi.org/10.3390/ijms18091865] [PMID: 28846632]
[52]
Satoo K, Noda NN, Kumeta H, et al. The structure of Atg4B-LC3 complex reveals the mechanism of LC3 processing and delipidation during autophagy. EMBO J 2009; 28(9): 1341-50.
[http://dx.doi.org/10.1038/emboj.2009.80] [PMID: 19322194]
[53]
Morell C, Bort A, Vara-Ciruelos D, et al. Up-regulated expression of lamp2 and autophagy activity during neuroendocrine differentiation of prostate cancer lncap cells. PLoS One 2016; 11(9)e0162977
[http://dx.doi.org/10.1371/journal.pone.0162977] [PMID: 27627761]
[54]
Ishaq S, Nunn L. Helicobacter pylori and gastric cancer: a state of the art review. Gastroenterol Hepatol Bed Bench 2015; 8(Suppl. 1): S6-S14.
[PMID: 26171139]
[55]
Cao Y, Luo Y, Zou J, et al. Autophagy and its role in gastric cancer. Clin Chim Acta 2019; 489: 10-20.
[http://dx.doi.org/10.1016/j.cca.2018.11.028] [PMID: 30472237]
[56]
Díaz P, Valenzuela Valderrama M, Bravo J, Quest AFG. Helicobacter pylori and gastric cancer: adaptive cellular mechanisms involved in disease progression. Front Microbiol 2018; 9: 5.
[http://dx.doi.org/10.3389/fmicb.2018.00005] [PMID: 29403459]
[57]
Qian HR, Yang Y. Functional role of autophagy in gastric cancer. Oncotarget 2016; 7(14): 17641-51.
[http://dx.doi.org/10.18632/oncotarget.7508] [PMID: 26910278]
[58]
Qin W, Li C, Zheng W, et al. Inhibition of autophagy promotes metastasis and glycolysis by inducing ROS in gastric cancer cells. Oncotarget 2015; 6(37): 39839-54.
[http://dx.doi.org/10.18632/oncotarget.5674] [PMID: 26497999]
[59]
Lin X, Peng Z, Wang X, et al. Targeting autophagy potentiates antitumor activity of Met-TKIs against Met-amplified gastric cancer. Cell Death Dis 2019; 10(2): 139.
[http://dx.doi.org/10.1038/s41419-019-1314-x] [PMID: 30760701]
[60]
Spirina LV, Usynin EA, Yurmazov ZA, Slonimskaya EM, Kondakova IV. Effect of Targeted Therapy With Pazopanib on Expression Levels of Transcription, Growth Factors and Components of AKT/m-TOR Signaling Pathway in Patients with Renal Cell Carcinoma Asian Pac J Cancer Prev 2017; 18(11): 2977-83.
[61]
Li W, Zhou Y, Yang J, et al. Curcumin induces apoptosis and protective autophagy in human gastric cancer cells with different degree of differentiation Zhonghua Zhong Liu Za Zhi 2017; 39(7): 490-6.
[http://dx.doi.org/10.3760/cma.j.issn.0253-3766.2017.07.003] [PMID: 28728293]
[62]
Fu H, Wang C, Yang D, et al. Curcumin regulates proliferation, autophagy, and apoptosis in gastric cancer cells by affecting PI3K and P53 signaling. J Cell Physiol 2018; 233(6): 4634-42.
[http://dx.doi.org/10.1002/jcp.26190] [PMID: 28926094]
[63]
Kong P, Zhu X, Geng Q, et al. The microRNA-423-3p-bim axis promotes cancer progression and activates oncogenic autophagy in gastric cancer. Mol Ther 2017; 25(4): 1027-37.
[http://dx.doi.org/10.1016/j.ymthe.2017.01.013] [PMID: 28254439]
[64]
YiRen H, YingCong Y, Sunwu Y, et al. Long noncoding RNA MALAT1 regulates autophagy associated chemoresistance via miR-23b-3p sequestration in gastric cancer. Mol Cancer 2017; 16(1): 174.
[http://dx.doi.org/10.1186/s12943-017-0743-3] [PMID: 29162158]
[65]
Li B, Wang W, Li Z, et al. MicroRNA-148a-3p enhances cisplatin cytotoxicity in gastric cancer through mitochondrial fission induction and cyto-protective autophagy suppression. Cancer Lett 2017; 410: 212-27.
[http://dx.doi.org/10.1016/j.canlet.2017.09.035] [PMID: 28965855]
[66]
Sun Y, Jiang Y, Huang J, Chen H, Liao Y, Yang Z. CISD2 enhances the chemosensitivity of gastric cancer through the enhancement of 5-FU-induced apoptosis and the inhibition of autophagy by AKT/mTOR pathway. Cancer Med 2017; 6(10): 2331-46.
[http://dx.doi.org/10.1002/cam4.1169] [PMID: 28857517]
[67]
Pei G, Luo M, Ni X, et al. Autophagy facilitates metadherin-induced chemotherapy resistance through the ampk/atg5 pathway in gastric cancer. Cell Physiol Biochem 2018; 46(2): 847-59.
[http://dx.doi.org/10.1159/000488742] [PMID: 29635244]
[68]
Zhou H, Yuan M, Yu Q, Zhou X, Min W, Gao D. Autophagy regulation and its role in gastric cancer and colorectal cancer. Cancer Biomark 2016; 17(1): 1-10.
[http://dx.doi.org/10.3233/CBM-160613] [PMID: 27314289]
[69]
Wang BJ, Zheng WL, Feng NN, et al. The effects of autophagy and pi3k/akt/m-tor signaling pathway on the cell-cycle arrest of rats primary sertoli cells induced by zearalenone. Toxins (Basel) 2018; 10(10): 398.
[http://dx.doi.org/10.3390/toxins10100398] [PMID: 30274213]
[70]
Wei WJ, Hardin H, Luo QY. Targeting autophagy in thyroid cancers. Endocr Relat Cancer 2019. pii: ERC-18-0502.R1. doi: 10.1530/ERC-18-0502
[http://dx.doi.org/10.1530/ERC-18-0502]
[71]
Yang M, Bai L, Yu W, et al. Expression of autophagy-associated proteins in papillary thyroid carcinoma. Oncol Lett 2017; 14(1): 411-5.
[http://dx.doi.org/10.3892/ol.2017.6101] [PMID: 28693184]
[72]
Su M, Mei Y, Sinha S. Role of the crosstalk between autophagy and apoptosis in cancer. J Oncol 2013; 2013102735
[http://dx.doi.org/10.1155/2013/102735] [PMID: 23840208]
[73]
Towers CG, Thorburn A. Therapeutic targeting of autophagy. EBioMedicine 2016; 14: 15-23.
[http://dx.doi.org/10.1016/j.ebiom.2016.10.034] [PMID: 28029600]
[74]
Wei B, Huang Q, Huang S, Mai W, Zhong X. Trichosanthin-induced autophagy in gastric cancer cell MKN-45 is dependent on reactive oxygen species (ROS) and NF-κB/p53 pathway. J Pharmacol Sci 2016; 131(2): 77-83.
[http://dx.doi.org/10.1016/j.jphs.2016.03.001] [PMID: 27032906]
[75]
Li C, Wang Y, Wang C, Yi X, Li M, He X. Anticancer activities of harmine by inducing a pro-death autophagy and apoptosis in human gastric cancer cells. Phytomedicine 2017; 28: 10-8.
[http://dx.doi.org/10.1016/j.phymed.2017.02.008] [PMID: 28478808]
[76]
Chen PP, Ma XY, Lin Q, et al. Kangfuxin promotes apoptosis of gastric cancer cells through activating ER‑stress and autophagy. Mol Med Rep 2017; 16(6): 9043-50.
[http://dx.doi.org/10.3892/mmr.2017.7716] [PMID: 28990095]
[77]
Wei F, Jiang X, Gao HY, Gao SH. Liquiritin induces apoptosis and autophagy in cisplatin (DDP)-resistant gastric cancer cells in vitro and xenograft nude mice in vivo. Int J Oncol 2017; 51(5): 1383-94.
[http://dx.doi.org/10.3892/ijo.2017.4134] [PMID: 29048624]
[78]
Valenzuela CA, Vargas L, Martinez V, Bravo S, Brown NE. Palbociclib-induced autophagy and senescence in gastric cancer cells. Exp Cell Res 2017; 360(2): 390-6.
[http://dx.doi.org/10.1016/j.yexcr.2017.09.031] [PMID: 28947133]
[79]
Pasquier B. Autophagy inhibitors. Cell Mol Life Sci 2016; 73(5): 985-1001.
[http://dx.doi.org/10.1007/s00018-015-2104-y] [PMID: 26658914]
[80]
Liu J, Xia H, Kim M, et al. Beclin1 controls the levels of p53 by regulating the deubiquitination activity of USP10 and USP13. Cell 2011; 147(1): 223-34.
[http://dx.doi.org/10.1016/j.cell.2011.08.037] [PMID: 21962518]
[81]
Shao S, Li S, Qin Y, et al. Spautin-1, a novel autophagy inhibitor, enhances imatinib-induced apoptosis in chronic myeloid leukemia. Int J Oncol 2014; 44(5): 1661-8.
[http://dx.doi.org/10.3892/ijo.2014.2313] [PMID: 24585095]
[82]
Byun S, Lee E, Lee KW. Therapeutic implications of autophagy inducers in immunological disorders, infection, and cancer. Int J Mol Sci 2017; 18(9): 1959.
[http://dx.doi.org/10.3390/ijms18091959] [PMID: 28895911]
[83]
Nagelkerke A, Sweep FC, Geurts-Moespot A, Bussink J, Span PN. Therapeutic targeting of autophagy in cancer. Part I: molecular pathways controlling autophagy. Semin Cancer Biol 2015; 31: 89-98.
[http://dx.doi.org/10.1016/j.semcancer.2014.05.004] [PMID: 24879905]
[84]
Hardie DG. AMPK and autophagy get connected. EMBO J 2011; 30(4): 634-5.
[http://dx.doi.org/10.1038/emboj.2011.12] [PMID: 21326174]
[85]
Zhou YY, Li Y, Jiang WQ, Zhou LF. MAPK/JNK signalling: a potential autophagy regulation pathway. Biosci Rep 2015; 35(3)e00199
[http://dx.doi.org/10.1042/BSR20140141] [PMID: 26182361]
[86]
Wang H, Wang L, Cao L, et al. Inhibition of autophagy potentiates the anti-metastasis effect of phenethyl isothiocyanate through JAK2/STAT3 pathway in lung cancer cells. Mol Carcinog 2018; 57(4): 522-35.
[http://dx.doi.org/10.1002/mc.22777] [PMID: 29278657]
[87]
Shen L, Shan YS, Hu HM, et al. Management of gastric cancer in Asia: resource-stratified guidelines. Lancet Oncol 2013; 14(12): e535-47.
[http://dx.doi.org/10.1016/S1470-2045(13)70436-4] [PMID: 24176572]
[88]
Digklia A, Wagner AD. Advanced gastric cancer: Current treatment landscape and future perspectives. World J Gastroenterol 2016; 22(8): 2403-14.
[http://dx.doi.org/10.3748/wjg.v22.i8.2403] [PMID: 26937129]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy